Diana Shu Yee Tan
YOU?
Author Swipe
View article: Low dose IL-2 administration prevents but fails to treat experimental autoimmune anti-myeloperoxidase glomerulonephritis
Low dose IL-2 administration prevents but fails to treat experimental autoimmune anti-myeloperoxidase glomerulonephritis Open
Background and hypothesis Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is a major cause of glomerulonephritis (GN) and kidney failure and current therapies are often limited by significant toxicity and limitation…
View article: Neutralizing the Th1 effector cytokines, IFN-γ and TNF-α, attenuates established experimental autoimmune anti-myeloperoxidase glomerulonephritis
Neutralizing the Th1 effector cytokines, IFN-γ and TNF-α, attenuates established experimental autoimmune anti-myeloperoxidase glomerulonephritis Open
Introduction This study investigates the therapeutic potential of blocking key CD4 + Th1 effector cytokines, TNF-α and IFN-γ, in experimental anti-myeloperoxidase (MPO) glomerulonephritis (GN). The immunopathogenesis of MPO autoimmunity is…
View article: Unravelling the Link between the Gut Microbiome and Autoimmune Kidney Diseases: A Potential New Therapeutic Approach
Unravelling the Link between the Gut Microbiome and Autoimmune Kidney Diseases: A Potential New Therapeutic Approach Open
The gut microbiota and short chain fatty acids (SCFA) have been associated with immune regulation and autoimmune diseases. Autoimmune kidney diseases arise from a loss of tolerance to antigens, often with unclear triggers. In this review, …
View article: Unravelling the Link between the Gut Microbiome and Autoimmune and Inflammatory Kidney Diseases: A Potential New Therapeutic Approach
Unravelling the Link between the Gut Microbiome and Autoimmune and Inflammatory Kidney Diseases: A Potential New Therapeutic Approach Open
Autoimmune kidney diseases arise from a loss of tolerance to antigens, often with unclear triggers. In this review we explore the role of the gut microbiome and how disease, diet and therapy can alter the gut microbiota consortium. Perturb…
View article: SAT-013 TOLEROGENIC CD40-DEFICIENT DENDRITIC CELLS ATTENUATE ANTI-MYELOPEROXIDASE VASCULITIS BY INDUCING REGULATORY B CELLS
SAT-013 TOLEROGENIC CD40-DEFICIENT DENDRITIC CELLS ATTENUATE ANTI-MYELOPEROXIDASE VASCULITIS BY INDUCING REGULATORY B CELLS Open
Tolerogenic dendritic cells (DCs) are an inviting immunosuppressive tool for the treatment of inflammatory diseases, but their therapeutic efficacy has not been tested in autoimmune renal vasculitis. Here, we sought to determine whether to…
View article: T cell tolerance in the modulation of autoimmune anti-myeloperoxidase ANCA-associated glomerulonephritis
T cell tolerance in the modulation of autoimmune anti-myeloperoxidase ANCA-associated glomerulonephritis Open
Autoimmune ANCA-associated glomerulonephritis (GN) is the most common of the severe crescentic forms of GN. It is closely associated with systemic small vessel vasculitis and autoimmunity to myeloperoxidase (MPO). The mechanisms of the bre…
View article: Myeloperoxidase Peptide–Based Nasal Tolerance in Experimental ANCA–Associated GN
Myeloperoxidase Peptide–Based Nasal Tolerance in Experimental ANCA–Associated GN Open
Less toxic treatment options for patients with myeloperoxidase (MPO)-ANCA-associated GN are needed. Using an established murine model of focal necrotizing GN mediated by autoimmunity to MPO (autoimmune anti-MPO GN), we assessed the capacit…